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During the last decades, new radionuclide-based targeted therapies have emerged as effi-
cient tools for cancer treatment. Targeted radionuclide therapies (TRTs) are based on a
multidisciplinary approach that involves the cooperation of specialists in several research
fields. Among them, radiobiologists investigate the biological effects of ionizing radiation,
specifically the molecular and cellular mechanisms involved in the radiation response. Most
of the knowledge about radiation effects concerns external beam radiation therapy (EBRT)
and radiobiology has then strongly contributed to the development of this therapeutic
approach. Similarly, radiobiology and dosimetry are also assumed to be ways for improving
TRT, in particular in the therapy of solid tumors, which are radioresistant. However, extrap-
olation of EBRT radiobiology to TRT is not straightforward. Indeed, the specific physical
characteristics ofTRT (heterogeneous and mixed irradiation, protracted exposure, and low
absorbed dose rate) differ from those of conventional EBRT (homogeneous irradiation,
short exposure, and high absorbed dose rate), and consequently the response of irradi-
ated tissues might be different. Therefore, specificTRT radiobiology needs to be explored.
Determining dose–effect correlation is also a prerequisite for rigorous preclinical radiobiol-
ogy studies because dosimetry provides the necessary referential to all TRT situations. It
is required too for developing patient-tailoredTRT in the clinic in order to estimate the best
dose for tumor control, while protecting the healthy tissues, thereby improving therapeu-
tic efficacy. Finally, it will allow to determine the relative contribution of targeted effects
(assumed to be dose-related) and non-targeted effects (assumed to be non-dose-related) of
ionizing radiation. However, conversely to EBRT where it is routinely used, dosimetry is still
challenging in TRT. Therefore, it constitutes with radiobiology, one of the main challenges
of TRT in the future.
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INTRODUCTION
This article, which is part of the inaugural series for the launch
of Frontiers in Nuclear Medicine, will discuss some of the main
challenges of radiobiology in targeted radionuclide therapy (TRT).
Investigating radiobiology and performing accurate dosimetry will
contribute to the improvement of the therapeutic efficacy of TRT,
especially in the case of solid tumors.
Radiobiology explores the biological effects of radiations. This
research field was created following the description of the first cases
of cutaneous erythema associated with the clinical use of radia-
tion at the beginning of the twentieth century. The use of X-rays to
treat patients with cancer was first experimented by V. Despeignes
in Lyon in 1896, 6 months after their discovery by W. Roentgen
(1). As early as 1902, the ability to quantify the delivered radiation
dose (dosimetry) and to establish the dose–effect relationship led
to a significant improvement of the patients’ outcome. In 1919,
dose fractionation started to be investigated by C. Regaud, at the
Curie Institute (Paris), who described how to treat tumors with
high absorbed doses, while protecting healthy tissues (2).
Most of what we know about radiobiology concerns exter-
nal beam radiation therapy (EBRT). Particularly, the therapeutic
efficacy of low (X and γ rays, electrons) and high linear energy
transfer (LET) radiation (neutrons, Auger electrons, protons,
alpha-particles, and heavy ions) has been extensively investigated.
This has been accompanied by the development of new tech-
niques and technologies for dose delivery to the tumor (3). Besides
total dose and LET, the biological effects of radiation depend on
the absorbed dose rate, absorbed dose fractionation, tissue oxy-
genation, and volume of irradiated tissue. In addition, the cell
response to radiation is highly dependent on the nature of the
irradiated tissue (genetic background, cell proliferation rate) and
its microenvironment.
CELLULAR RADIOBIOLOGY
INITIAL EVENTS
Ionizing radiations interact with biological substrates through
direct and indirect mechanisms (4). Direct effects involve
one-electron oxidation reactions, while indirect effects are
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mediated through water dissociation, leading to the production of
reactive oxygen species (ROS), such as superoxide radicals
(
O·−2
)
and hydrogen peroxide (H2O2), the precursors of the highly dam-
aging hydroxyl radicals (·OH). Noteworthy, these ROS are similar
to those produced by endogenous sources, such as the mitochondr-
ial oxidative metabolism (leading to O·−2 formation during oxygen
reduction), the plasma membrane-bound nicotinamide adenine
dinucleotide phosphate [NAD(P)H] oxidases and lipoxygenases
(5–7) and peroxisomes (formation of H2O2). Massive production
of ROS and of reactive nitrogen species (RNS) is also mediated by
activation of cyclooxygenase-2 (COX-2) and inducible nitric oxide
synthase (iNOS), for instance, following induction of transcription
factors involved in the inflammatory response, such as nuclear fac-
tor kappa B (NF-κB) or activator protein-1 (AP-1) (8). NF-κB is
activated by ataxia telangiectasia mutated (ATM), the main protein
involved in DNA damage recognition. COX-2 leads to produc-
tion of prostaglandin-E2 and ROS that are released in the intra-
and extra-cellular medium (9) and contribute to the inflammatory
responses (8) (Figure 1). Activation of iNOS leads to the formation
of nitric oxide (NO) that can react with superoxide anion to form
RNS, such as peroxynitrite
(
ONO−2
)
(10–12). ONO−2 and NO
are produced by macrophages during inflammatory reactions, but
they are also released by irradiated cells (12). ONO−2 can generate
many of the degradation products observed with ·OH (9). More-
over, differently from ·OH that is very reactive and diffuses for only
about 4 nm, ONO−2 can diffuse easily within cells and its highly
oxidizing protonated form (ONOH) can cause DNA damage, cell
death as well as protein and lipid peroxidation. H2O2 and NO can
diffuse between cells (4).
Therefore, ROS and RNS participate in physiological processes
including cell signaling, immune response, inflammation, apop-
tosis, and cell growth, and also in the cell response to radiation (8).
These endogenous and exogenous reactive species can cause cel-
lular damage, when imbalance occurs between their production
and their destruction by the cell enzymatic and non-enzymatic
defense systems. For instance, O·−2 can be reduced to H2O2 by the
enzyme superoxide dismutase. H2O2 can in turn be reduced to
water by the catalase or glutathione peroxidase enzymes, or can
be used, in the presence of metal ions, such as Fe2+, to produce
·OH through the Fenton reaction. Superoxide dismutase, cata-
lase, and glutathione peroxidase are part of the enzymatic defense
system developed by cells to keep the level of these endogenous
ROS as low as possible. Several intracellular components, particu-
larly glutathione, urates, bilirubin, and vitamin E and C, can also
FIGURE 1 |Targeted and non-targeted biological effects in conventional
external beam radiotherapy. Targeted effects are caused by one or more
particles traversing irradiated cells and can be divided in DNA and
non-DNA-centered effects. Non-targeted effects describes the effects
observed in cells that have not been directly traversed by particles but that are
close to irradiated cells, as well as long-distance effects. DNA, mitochondria,
and the cell membrane are the main sensitive targets of radiation. Following
targeted and non-targeted effects, cells can survive (lesions are effectively
repaired), they can die (lesions are not repaired) or they can be transformed.
The dose–effect relationship of targeted effects is commonly fitted by linear or
linear-quadratic models. A saturation of the response to non-targeted effects
has been described. For more details, see the main text.
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act as radical scavengers. When the balance is tilted in favor of
reactive species, all cell compartments (cell membrane, mitochon-
dria, and particularly the nucleus) and constituents (DNA, lipids,
and proteins) may be harmed and their functions altered.
DNA DAMAGE
Radiation-induced oxidative DNA damage resulting from ·OH
attack (indirect effect, water radiolysis) or from one-electron oxi-
dation (direct effect) includes single-strand (SSB) and double-
strand DNA breaks (DSB), DNA base damage (oxidized and abasic
sites), and DNA–DNA or DNA–protein crosslinks.
The main reactions of radiation-induced radicals with DNA are
hydrogen abstraction from deoxyribose molecules by ·OH (mainly
from the C’ carbon of the sugar moiety) and ·OH addition to thepi
bonds of the bases [for reviews see Ref. (4, 13, 14)]. It is estimated
that about 80% of ·OH radicals react with bases and the remain-
ing 20% with sugar moieties. Hydrogen abstraction from the C2 of
the sugar moiety can result in base loss or SSB formation through
phosphate elimination. SSBs can also be produced after ·OH reac-
tion with pyrimidine bases. DSBs can be caused by the attack of
one or two ·OH radical species. However, it is very unlikely that a
segment of a few DNA bases will be affected by two independent
radiation events (between 10–6 and 10–4 Gy–1 for direct and indi-
rect effects, respectively). Indeed, at biologically relevant doses, it
is more probable that a single radiation track might induce ion-
ization on opposite strands in close proximity. Therefore, DSBs
can be produced after DNA denaturation consecutive to two SSBs
occurring within a 20-bp stretch.
DNA damage incidence is proportional to the absorbed dose
and is quantified per Gy and per cell, after exposure to low and
high LET radiation (15). About 40 DSBs are formed per cell
per Gy of low-LET radiation. DNA base lesions are the most
abundant (about 1000/cell/Gy) and fourteen types of oxidative
purine and pyrimidine DNA damage have been detected in cellular
DNA, among which 8-oxo-7,8-dihydroguanine (8-oxoGua) and
5,6-dihydroxy-5,6-dihydrothymine (thymine glycol) are the most
frequent (4). Although DSB frequency is quite low, cell survival
and mutagenesis are highly dependent on DSB spatial distribu-
tion. About 150 DNA–protein and 30 DNA–DNA crosslinks are
also estimated to be produced per Gy and per cell (15).
Accumulation of DNA damage can lead to even more complex
lesions called locally multiply damaged sites (LMDS), also known
as oxidative clustered DNA lesions (OCDLs) (16–18). LMDS occur
when more than two lesions are produced within one or two
helices, i.e., within 20 bp. These clustered DNA lesions include
complex SSBs and also simple or complex DSBs. They may include
up to 10 lesions in the case of low-LET radiation and even more
complex damage with high LET radiation. Thus, although low and
high LET radiation produce the same DNA lesions, their yield and
spatial distribution are different.
DNA DAMAGE REPAIR SYSTEMS
Cells have developed DNA damage repair (DDR) systems against
DNA lesions. DNA damage activates sensor systems, such as ATM,
Ataxia Telangiectasia, and Rad 3-related (ATR), which in turn
induce signaling pathways involved in the cell response to radia-
tion, including cell cycle arrest, DNA repair, or cell death (19–22).
DNA base damage is mostly repaired by the base excision repair
(BER) mechanism and to a lesser extent by the nucleotide exci-
sion repair (NER) mechanism (23, 24). DSB repair schematically
involves two major recombination pathways. The first one is the
homologous recombination (HR) system that is active specifically
in the S and G2 phases of the cell cycle (25). It is an error-free mech-
anism because undamaged DNA (the sister chromatid) is used
as template for DNA repair. The second mechanism is the non-
homologous end-joining (NHEJ) system, which is active mainly
in the G1 phase of the cell cycle (26). Although NHEJ is the main
repair pathway used by irradiated cells, it is thought to be error-
prone because the broken DNA ends are ligated without the need
of an undamaged, homologous template.
When accurately repaired, DNA lesions have no effect on cell
survival or in daughter cells. However, if the lesions are too com-
plex or abundant, or if the cell DNA repair machinery is deficient,
not all DNA lesions will be completely or correctly repaired.
Unrepaired/misrepaired DNA damage can cause the formation
of chromosomal aberrations when cells progress through the cell
cycle, leading to mitotic catastrophe (cell death during mitosis) or
to programed cell death (known as apoptosis). Not all unrepaired
lesions are lethal for the cell. In this case, they may be passed to
the daughter cells and could lead to mutations, genomic instability
and eventually to cancer development (Figure 1).
A DNA-CENTERED APPROACH
According to the DNA-centered view of radiation-induced dam-
age, unrepaired DNA lesions are the lethal event leading to cell
death. The concerned DNA lesions are mainly DSBs, but more
complex damage, involving OCDLs, may also constitute lethal
lesions. As the aim of radiation therapy is to kill tumor cells or
at least to prevent their division, the clonogenic assay, which was
developed by Puck and Markus in 1956 to investigate the ability of
a cell to form a new colony, has become the reference technique for
assessing the cell response to radiation (27). This assay shows that
the clonogenic survival of irradiated cells decreases exponentially
as a function of the mean absorbed dose. Plotted on a graph, the
survival logarithm can be experimentally fitted by a linear or a
linear-quadratic regression model, depending on whether high or
low-LET radiation is used. The linear part (αD) of the equation
corresponds to single-hit killing events, while the quadratic part
(βD2) requires two hits to kill cells (Figure 1). Thus, the overall
cytotoxic effect is due to the sum of single and double hit events.
This interpretation of cell cytotoxicity corresponds to the so-called
target theory, which is an essential concept for understanding radi-
ation biology. The fundamental principle of the target theory is
that inactivation of the target(s) by a lethal event requires the cells
to be crossed by radiation. The shape of the survival curve can be
affected by the tissue radiation sensitivity that is defined by the
α/β ratio and represents the cell capacity to repair damage. Radi-
ation sensitivity, which was first hypothesized by Bergonié and
Tribondeau in 1905 (28), is essentially explained by the patient’s
genetic background concerning the DNA repair enzymes, antiox-
idant defenses and tissue proliferation. For instance, patients with
pathologies like Ataxia Telangiectasia, Xeroderma Pigmentosum,
Cockayne, or Nijmegen breakage syndromes have defects in pro-
teins involved in DNA DSBs repair and show hypersensitivity to
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radiation (29–31). The shape of the survival curves is also affected
by the LET, tissue hypoxia and dose fractionation, as shown in the
60s by Barenden and colleagues (32–36). The relevance of the α/β
ratios determined in vitro in human cell lines for understanding
the in vivo values has been extensively reviewed (37, 38).
NEW PARADIGMS IN RADIATION BIOLOGY: NON-DNA
CENTERED AND NON-TARGETED EFFECTS
For about a century, the paradigm of radiation biology has been
that the biological effects of ionizing radiation occur only in the
nucleus of cells crossed by particles and that cell death is strictly
due to unrepaired or misrepaired DNA. Therefore, the biologi-
cal effects of ionizing radiation should be strictly related to the
energy absorbed by the tissues and the survival of irradiated cells,
expressed as a function of the dose, should be strictly fitted by a
linear or linear-quadratic curve explained by DNA hits. However,
such DNA-centered approach is not fully satisfying. For instance, it
cannot explain hypersensitivity to low doses and radiation sensitiv-
ity syndromes associated with mutation of cytoplasmic proteins.
In addition, studies in cells, animal models, or patients treated
by radiotherapy reported that biological effects could be observed
also when only the cell cytoplasm was irradiated (known as non-
DNA-centered effects) and in non-irradiated areas (known as non-
targeted effects or bystander effects) (39–42). As early as 1922, the
release of stress mediators in the serum of irradiated mice (43) or
in blood samples from irradiated patients (44–46) was associated
with long-distance bystander effects called abscopal effects. The
concept of bystander effects emerged again in 1992 when Naga-
sawa and Little reported that in monolayer cell cultures exposed to
alpha micro-beams, sister chromatid exchanges were observed in
30% of cells, although <1% of cells were crossed by particles (47).
Since then, many studies have investigated the origin and nature of
radiation-induced bystander effects that are defined as biological
effects occurring in the neighborhood of irradiated cells (47).
Bystander effects include mutations, clastogenic effects, cell
death, apoptosis, and cell transformation (6). They mainly occur
after low dose (<1 Gy) or low dose-rate irradiation, although
they have been observed in EBRT also after high absorbed dose
(10 Gy). They involve signaling from irradiated cells toward non-
irradiated cells. Specifically, stress mediators are transmitted to
bystander cells by cell–cell interactions through gap junction inter-
cellular communication (GJIC) when cells are in contact and the
molecules are small (<1500 Da) (Figure 1), or by the release of sol-
uble damage/stress signals that may have distant biological effects
(abscopal effect) (6, 48–50). These mediators can be ROS/NO,
cytokines (interleukin 8, interleukin 6, tumor necrosis factor, and
interleukin-33), Ca2+, or extracellular DNA (ecDNA). They are
produced by irradiated cells and are released in the extracellular
environment (39), thus inducing oxidative stress in neighbor-
ing cells/tissues. However, they can be active also within the cell
in an autocrine way. They can also activate immune cells (for
instance, macrophages and T lymphocytes) that, in turn, release
cytokines, leading to iNOS induction, and NO formation (51).
Therefore, the inflammatory and radiation responses share com-
mon mechanisms to promote and perpetuate a harmful inflamma-
tory/oxidative stress environment. This new paradigm also high-
lights the role of the tumor (or healthy tissue) microenvironment
in the radiation response. The finding that ROS scavengers, such
as DMSO, abolish the bystander response indicates that oxida-
tive stress plays a major role in this phenomenon (52). While
·OH have a short life and interact within few nm, other species,
such as H2O2 and NO, can migrate across the plasma membrane
and cause oxidative damage in neighboring cells. Moreover, other
systems leading to sustained intercellular production of reactive
radicals can be activated in neighboring cells after cytokine release
by irradiated cells or binding of immune cells to bystander cells.
Interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and
interleukin-33 (IL-33), for instance, activate NF-κB that is involved
in the expression of the COX-2 and iNOS genes, which participate
in the inflammatory response and the local production of ROS
and NO, respectively (Figure 1). Furthermore, TNF-α, interleukin
8, and transforming growth factor 1 b (TGFβ-1b) can activate the
mitogen-activated protein kinase (MAPK) pathways [extracellu-
lar signal-related kinase (ERK), c-JUN N-terminal kinase (JNK),
and p38] that participate in COX-2 and iNOS up-regulation (11,
53). Interleukin 6 is released by irradiated macrophages and acti-
vates Janus-kinase 2 (JAK2)-signal transducer and activator of
transcription 3 (STAT3). STAT3 contributes to NFκ-B retention
in the nucleus and thereby in the induction of COX-2 and iNOS
expression (54, 55). TGFβ-1 secreted by irradiated cells can also
activate NADPH oxidase, which is located at the cell membrane
and is involved in bystander ROS and NO production. There-
fore, bystander factors are involved in the long-term production
of reactive radicals in a feed-forward and self-sustaining fashion
and in the creation of an inflammatory environment, leading to
the recruitment of immune cells (52). Noteworthy, the increase in
intracellular oxidative stress leads to mitochondrial dysfunction
that can further exacerbate oxidative processes by releasing ROS
and RNS.
Finally, it has been shown that different signaling pathways are
involved in DNA repair, depending on whether DNA damage is
produced directly by irradiation, or indirectly by oxidative stress-
induced bystander effects (56). Moreover, while targeted biological
effects increase with the dose in EBRT, a saturation response is
observed when non-targeted effects are involved, and above a
certain dose, no additional effect is observed (Figure 1).
NEW PARADIGMS IN RADIATION BIOLOGY:
EXTRA-NUCLEAR TARGETS
CELL MEMBRANE
Although most attention has been focused on DNA as the main
radiation target, the idea that the membrane could also be an
important target was suggested in 1963 by Alper et al. (57). The
cell membrane is now recognized as a key player in the radiation-
induced biological effects. Its role in the cellular response to
radiation may be explained by its function in many signal-
ing pathways, including apoptosis (58–60). Radiation-induced
hydroxyl radical molecules can attack not only nuclear DNA
but also polyunsaturated fatty acid residues of membrane phos-
pholipids. This results in the formation of malonedialdehyde or
4-hydroxynonenal that can induce DNA–protein crosslinks (58).
Radiation can also cause activation of acid sphingomyelinase
that hydrolyzes sphingomyelin in the cell membrane to produce
ceramide and phosphorylcholine (59–62). Ceramide is a second
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messenger of apoptosis and is also involved, when associated with
cholesterol, in the formation of ceramide-enriched platforms (also
known as lipid rafts) containing signaling and transport proteins.
These platforms play a central role in cellular functions such as
cell signaling and trafficking. Specifically, plasma membrane acti-
vation stimulates diverse signaling pathways that are mediated by
the MAPK superfamily, including ERK1/2, JNK, and p38. More-
over, lipid rafts contain NADPH oxidase that is involved in the
sustained ROS/RNS production by bystander cells. NADPH can be
activated by TGFβ secreted by irradiated cells after activation of cell
membrane receptors by cytokines (TGFβ, TNFα, interleukins) and
Ca2+ ion channels. These indirect effects can be partially inhib-
ited by antioxidants, such as vitamins E and C, and by the enzymes
superoxide dismutase, catalase, and glutathione peroxidase.
MITOCHONDRIA
Mitochondria are central cell organelles. They are involved in cell
respiration by reducing O2 into O
·−
2 during ATP production and
constitute one of the main source of endogenous ROS and RNS
(8, 63). They also play a role in radiation-induced cell signal-
ing pathways, such as apoptosis (64). Indeed, one of the critical
events is the change in mitochondrial membrane potential lead-
ing to leakage and release in the cytosol of pro-apoptotic proteins,
including cytochrome C and apoptosis-inducing factor (10). This
may be due to high ROS and NO production in response to
direct irradiation or non-targeted effects. Moreover, ROS, such
as superoxide anions, released by mitochondria can contribute
to intracellular oxidative stress and non-targeted effects through
their conversion into diffusible H2O2 molecules (52).
Mitochondrial DNA can also be altered after ROS attack or by
direct radiation effects (65–67). Mitochondrial DNA is very sensi-
tive to oxidative stress because it is not protected by histones, and
mutations or deletions have been observed. When they concern
the genes coding for mitochondrial ATPase, NADH dehydroge-
nase complex I and cytochrome c oxidase, they can lead to defects
in the mitochondrial metabolism and the DNA repair efficiency
as well as to the increase in ROS level. These effects have been
observed both in directly irradiated cells and in non-targeted cells.
TARGETED RADIONUCLIDE THERAPY
Beside EBRT improvements, TRT has emerged as an attractive
approach for treating tumors during the twentieth century. In
TRT, a radionuclide is coupled to a vector [for instance, mono-
clonal antibodies (mAbs) or peptides] directed against cancer cells
or their environment to specifically irradiate only the tumor tar-
gets. Therefore, TRT is particularly attractive when conventional
EBRT (CEBRT) cannot be used due to unacceptable toxicities
toward healthy tissues. This is the case of disseminated disease,
metastases, or tumors located in close vicinity of sensitive organs.
Compared to chemotherapy, it offers the possibility to specifically
target tumor cells, thereby reducing the side effects, and also to
treat distant tumor cells (which cannot be directly reached by the
drug) through cross-fire irradiation (i.e., energy deposition in cells
that are not specifically targeted) (Figure 2).
FIGURE 2 |Targeted and non-targeted effects in targeted
radionuclide therapy. Targeted effects are caused by one or more
particles crossing irradiated cells and can be due to self-irradiation and
cross-fire irradiation. Non-targeted effects include effects observed in
cells close to irradiated cells and also long-distance effects. The
nature of the dose–effect relationship resulting from targeted and
non-targeted effects needs to be determined. For more details, see the
main text.
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Radionuclide therapy started in the 20–40s when injections
of very simple chemical forms of a radionuclide (131I or 32P)
were used to treat patients with differentiated thyroid or ovar-
ian cancers, respectively. Other compounds have been largely
employed in nuclear medicine, such as 89SrCl2, 153Sm-EDTMP,
or 186/188Re–HEDP, for palliative treatment of bone metastases.
Radio-embolization with 90Y microspheres has been used for the
treatment of hepatocellular carcinoma. In 2013, 223Ra chloride
(Xofigo®) was the first Food and Drug Administration (FDA)-
approved unsealed α-emitting radiopharmaceutical for the treat-
ment of patients with castration-resistant prostate cancer and
metastatic bone disease. Radionuclides can also be bound to a vec-
tor that specifically targets tumor cells for TRT. Specific molecules,
such as metaiodobenzylguanidine (mIBG) labeled with 131I for
TRT of neuroblastoma and medullary thyroid cancer, have been
progressively developed. Peptide receptor radionuclide therapy
(PRRT) started to be assessed in the 70–80s and led to the devel-
opment of 90Y-DOTATATE and 90Y-DOTATOC that are currently
used for the treatment of neuroendocrine tumors. In radioim-
munotherapy (RIT), antibodies against cancer cell antigens are
used to target the radionuclide to cancer cells. In RIT, the radiation-
induced biological effects may be combined with the antibody
cytotoxic effect. The first RIT assays in patients using 131I-labeled
polyclonal antibodies against cancer cell antigens were performed
in 1953. The first clinical trials with mAbs (131I-labeled or 67Cu-
labeled anti-HLA-DR mAbs) began in 1988 and 131I-labeled anti-
CD20 antibodies were first used in patients with non-Hodgkin
lymphoma (NHL) in 1993. Two radiopharmaceuticals for RIT
have been approved by FDA (90Y-ibritumomab tiuxetan, Zevalin®,
in 2002 and 131I–tositumomab,Bexxar®, in 2003) for the treatment
of relapsed or refractory low-grade, follicular, or transformed B-
cell lymphoma (68). NHL is undoubtedly the disease in which RIT
has the highest success rates. Indeed, the overall response rate is
between 60 and 83% in previously treated patients and of 95% in
patients treated for the first time (69) compared to 56% in patients
treated with rituximab immunotherapy (68). As the Zevalin® and
Bexxar® activities administered to patients are currently based
only on the patient’s weight (MBq/kg for Zevalin®) or on deliv-
ering 75 cGy to the whole body (Bexxar®), further improvements
could be expected by planning patient-tailored treatments using a
dosimetry approach.
On the other hand, TRT of solid tumors is more challeng-
ing, mainly because these tumors are more radiation-resistant
than lymphomas. In such context, the approach consisting in one
injection of the maximal tolerated activities of a radiopharmaceu-
tical, based on the patient’s weight, is not sufficient and a more
complex strategy is required (70–73) that takes into account both
radiobiology and dosimetry data.
TRT RADIOBIOLOGY SPECIFICITY
Although particles emitted by radionuclides produce similar phys-
ical events (ionization/excitation) as those described in EBRT, TRT
radiobiology cannot be strictly extrapolated from the radiobiology
developed for EBRT.
The main differences between EBRT and TRT concern the
absorbed dose-rate and the spatial energy deposit (Figure 3).
CEBRT produces homogeneous irradiation at high absorbed dose
rate (about 1–2 Gy·min−1) of low-LET X-rays that target all the
FIGURE 3 | Comparison of conventional external beam radiotherapy and targeted radionuclide therapy.
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cells in the field with a total absorbed dose of 40–80 Gy, admin-
istered in fractions of 2 Gy, five fractions per week. Conversely,
TRT is characterized by low absorbed dose rate (<1 Gy·h−1) with
protracted, heterogeneous, and mixed irradiation. Indeed, vec-
tors can be coupled to radionuclides that emit beta, alpha, or
Auger electrons, associated or not with X or γ rays. In addi-
tion, when using alpha particle emitters, the decay spectrum of
daughter radionuclides should also be taken into account. There-
fore, LET ranges from 0.2 keV/µm for beta, X, and γ rays and
4–25 keV/µm for Auger electrons to 50–230 keV/µm for alpha
particles (Figure 3). The particle path length will be also variable:
few nm–µm for Auger electrons,fifty to about one hundredµm for
alpha particles and from µm to mm for beta particles. Finally, the
distribution of radiolabeled molecules is generally non-uniform
and leads to strong heterogeneity in activity distribution, what-
ever scale considered (subcellular, organ, or organism). Therefore,
some territories will be irradiated while others may partly escape.
This phenomenon is even more marked for short range emit-
ters, such as alpha particle and Auger electron emitters, because
the path length of the emitted particles produces low cross-fire
irradiation (i.e., cells are crossed by particles emitted by radiola-
beled vectors bound to neighboring cells) (Figure 2). However,
the highly localized energy deposition associated with Auger elec-
trons and alpha particles is also an attractive tool to investigate
the biological effects of ionizing radiations at the subcellular scale
and has shown the weaknesses of a completely DNA-centered con-
ception of TRT effects. Indeed, we and others have demonstrated
that extra-nuclear targets are also involved in targeted and non-
targeted responses (74–78). The existence of non-targeted effects
may affect the absorbed dose–effect relationship.
IMPROVING DOSIMETRY IN TRT
One difficulty when investigating TRT radiobiology is that in
many preclinical and clinical studies, dosimetry is not available
or is not fully accurate. Biological effects are often related to the
activities injected in patients/animal models (Bq/kg) or added to
the medium of cultured cells in in vitro experiments (Bq/mL).
However, like for EBRT, dose assessment is, at least theoretically,
the only reference parameter common to all forms of treatment
involving radiation and the dose–effect relationship provides use-
ful information on how radiations act. In TRT, the biological
effects observed in patients/animal models or in cultured cells will
depend on the used activity, its distribution within the different
compartments (organs, cell compartments), its pharmacokinet-
ics/dynamics, the type of emission,and the target geometry (organ,
cells, nucleus) and also, like for EBRT, on the nature of the targeted
tissue and its microenvironment.
Therefore, dosimetry is a requirement for the radiobiologist;
however, determining the absorbed dose is not straightforward
in TRT and is often considered a tedious and unattractive task.
The approach commonly used is based on the medical internal
radiation dose (MIRD) formalism (79):
D(rT ,TD) =
∑
rS
A˜(rs ,TD) S(rT ← rS)
The MIRD formalism requires to determine the cumulative num-
ber of decays ÃrS, which is the time integrated activity (or total
number of decays) occurring in a source region rS over the dose
integration period TD, and the corresponding S values, which
represent the absorbed dose in the target region rT per nuclear
transformation in rS.
Determining the activity distribution and S values
The reliability of the radiation dose estimates in preclinical and
clinical TRT studies is directly related to the accuracy of the activ-
ity assessment at each time point over the considered period.
For instance, in in vitro experiments, the uptake of radioactiv-
ity per cell is assessed at various intervals after exposure to the
radiolabeled vector. For this, the radioactivity distribution within
the cell population needs to be considered (80). Moreover, the
subcellular distribution may be different depending on the tar-
geting vector and on the final source (cell membrane, cytoplasm,
organelles, or nucleus) according to the MIRD formalism. For
animal experiments, several methodologies are now available.
The standard method relies on the determination of the average
radioactivity in different organs after animal sacrifice at various
time points following administration of the radiopharmaceuti-
cal. This approach can be completed by digital autoradiography
that provides information about the spatio-temporal distribution
of radioactivity in tissue cryosections (81). The development of
small animal imaging techniques (micro-SPECT-CT or micro-
PET-CT) provides an attractive alternative method by reducing
the number of needed animals and allowing longitudinal stud-
ies (82, 83). However, because of the inherent limits of these
imaging techniques, the determination of radioactivity is lim-
ited to organs showing specific targeting. In the clinic, dosimetry
is routinely used in EBRT; conversely, TRT dosimetry is still in
its early days and it is much more difficult. Initially, conven-
tional methods based on planar imaging were used to assess the
radioactivity distribution. However, it is now clear that, due to the
inherent heterogeneity of the distribution of a radiopharmaceu-
tical in tissues, three-dimensional anatomical (CT or MRI) and
functional [PET or single-photon emission CT (SPECT)] imaging
approaches are required and that the S value must be calculated
using Monte Carlo simulations. However, these techniques are
much more demanding in terms of human and methodologi-
cal resources and uncertainties in the radiation dose estimation
may still arise from incomplete kinetic assays and low accuracy
in volume measurements and S value calculation (84). In both
clinical and preclinical studies, S values (i.e., the absorbed dose
per decay) can be determined using Monte Carlo codes that
allow following the radiation transport and scoring the energy
deposit (85–87). For this purpose, the cell, organ, or organism
geometry must be known (87, 88). This can be done by micro-
scopic observation of cells in vitro, and by using phantoms or
the information provided by CT scans for animal models and
patients.
Determining dose–effect relationship
Unfortunately, very few preclinical studies are available to demon-
strate the validity in TRT of the linear quadratic or linear dose–
effect relationship, as commonly observed in EBRT. In clinical
TRT studies, interesting and encouraging results on the correla-
tion between tumor-absorbed dose and treatment efficacy have
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been highlighted (89, 90), although no strong dose–effect rela-
tionship has been shown even in lymphoma (91), which is the
disease most frequently treated by TRT. Strigari et al. reported
that among 79 radiotherapy studies investigating dosimetry, an
absorbed dose–effect correlation was found in 48 (92). Yet, the
existence of a dose–effect relationship (efficacy/toxicity) in TRT
is still a matter of debate. Besides performing accurate dosime-
try, the most relevant biological endpoints must also be identified.
Indeed, the follow-up of tumor shrinkage in patients is difficult
because TRT is mainly used to treat small-volume solid tumors
or disseminated disease. Therefore, other parameters, such as the
clinical response or progression-free survival, should be investi-
gated as endpoints to evaluate TRT efficacy and the dose–effect
relationship (90, 93).
The link between absorbed dose and associated toxicities in
healthy tissues (based on the creatinine level for kidney toxic-
ity, blood cell count for bone marrow toxicity, or liver functional
parameters) has also been studied in several targeting models,
including PRRT (94). Therapeutic regimens could then be based
on the maximal absorbed dose tolerated by healthy tissues rather
than on the dose delivered to the tumor.
INVESTIGATING THE “INVERSE DOSE RATE-EFFECT” PHENOMENON
In TRT, the absorbed dose rate depends on the physical half-life
of the radionuclide, its specific activity and the vector pharma-
cokinetics (transit, uptake, and clearance). Therefore, irradiation
is usually protracted from hours to days and the generally low
absorbed dose-rate values (<1 Gy·h−1) are expected to give cells
time to repair damage. As the clonogenic survival of cells decreases
when the dose or dose rate increases, TRT efficacy should there-
fore be very low. However, this is not true and TRT therapeutic
efficacy per Gy, when accurate dose determination is available, is
higher than that of CEBRT (95, 96). The observation that low
absorbed dose rates are ultimately more cytotoxic per Gy than
doses delivered at high dose rate is defined as the inverse dose
rate-effect. It has been described also after low dose of EBRT
and could contribute to the hypersensitivity to low doses (95, 97–
99). Several hypotheses have been proposed to explain this effect,
including TRT-mediated synchronization of cells in a radiosen-
sitive cell cycle phase or defects in the detection of low levels
of DNA damage. However, these mechanisms cannot be gener-
alized (78) and TRT biology still needs to be investigated for each
TRT situation. Models and notions have been developed to reduce
the discrepancies between the theoretical dose–effect relationship
and the real biological effects measured in human patients using
clearly identified endpoints (creatinine values, for example). The
notion of biological effective dose (BED) has been introduced
to take into account the biological effects of low absorbed dose
rates and the repair capacities allowed by protracted irradiation,
as it is done for fractionation in EBRT. The concept of equiva-
lent uniform biologically effective dose (EUBED) is used to take
into account the dose distribution heterogeneity (100). However,
these improvements might not be enough if all the aspects of
radiobiology of the tissues treated by TRT have to be taken into
account. For example, in most TRT dosimetric approaches, α/β
are still extrapolated from EBRT data and these values should be
confirmed (101, 102).
INVESTIGATING NON-TARGETED EFFECTS IN TRT
As non-targeted effects have been described mostly after low doses
of EBRT, their contribution in TRT (50, 103–106) should be more
prominent because the dose is generally delivered at low dose
rates (104). Therefore, the final TRT cytotoxicity could be the
sum of both targeted effects (described by the absorbed dose–
effect relationship) and non-targeted effects, which are likely to be
described by the lack of absorbed dose–effect relationship and a
saturated response. Therefore, the nature of the global absorbed
dose–effect relationship, resulting from both phenomena, needs
to be investigated.
Although the analysis of non-targeted effects in TRT is more
challenging than in EBRT, several in vitro and in vivo studies have
shown that beta-emitting particles, such as those released by 3H
incorporated into DNA (thymidine (3H-dThd) or by 131I incorpo-
rated in metaiodobenzylguanidine (131I-MIBG), and Auger elec-
trons emitted by 125I coupled to deoxyuridine (125IUdR) (26) or to
antibodies (106) could lead to non-targeted effects. This was also
observed when alpha-particle emitters (213Bi, 211At) were used
to radiolabel mAbs (74, 75) or MIBG (105, 107), respectively.
Moreover, drugs that interfere with gap junctions (for instance,
lindane) or that scavenge ·OH radicals (DMSO) can abrogate the
non-targeted response in a cell model of TRT (108).
The relative contribution of non-targeted effects, compared to
the direct effects of radiation, may depend on the TRT nature
and specifically on the absorbed dose rate and LET (105–107).
One could expect TRT to behave like EBRT for long-range par-
ticles, thereby producing homogenous irradiation and for situa-
tions with high tumor uptake of radioactivity, thereby producing
high dose–rate irradiation. However, this needs to be further
confirmed.
CONCLUSION
Although the methodology for exploring radiation biology in con-
ventional EBRT is well established, a specific method dedicated
to TRT needs to be developed. This involves a solid dosimetry
approach that takes into consideration the different TRT situations
and that may become the reference. Moreover, the absorbed dose
and absorbed dose rate are likely to be the critical parameters in
the radiobiological response to TRT. The relative contribution of
targeted and non-targeted effects in the organ and tissue responses
to TRT needs also to be determined.
Preclinical experiments offer the possibility to study in simple
models how TRT acts on cells and tissues with the aim of iden-
tifying the specific molecular and cellular mechanisms, as it has
been done in EBRT. They might provide ways for improving TRT
by taking into account both radiobiology and dosimetry to shift
from a radioactive chemotherapy approach toward true targeted
radiotherapy.
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